Corante

About this Author
Derek Lowe
Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: derekb.lowe@gmail.com Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Emolecules
ChemSpider
Synthetic Pages
Organic Chemistry Portal
PubChem
Not Voodoo
DailyMed
Druglib
Clinicaltrials.gov

Chemistry and Pharma Blogs:
The Science Business
Org Prep Daily
Kilomentor
On Pharma
Kinase Pro
Pharma Conduct
Chemical Quantum Images
The LouRoe
One in Ten Thousand
Intermolecular
Periodic Tabloid
Chemical Musings
C&E News Blog
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Chirality
Mad Chemist Chick
BBSRC/Douglas Kell
Drug Discovery Opinion
The Chemblog
Realizations in Biostatistics
Molecule of the Day
Chemjobber
Pharmalot
WSJ Health Blog
Chemical Crystallinity
ChemSpider Blog
Pharmagossip
Med-Chemist
Organometallic Current
Useful Chemistry
Chiral Jones
Great Molecular Crapshoot
No Name No Slogan
SimBioSys
Culture of Chemistry
The Curious Wavefunction
Chemical Sabbatical
Natural Product Man
Totally Synthetic
Zusammen
My Chemical Journey
The F- Blog
Generally Chemistry
Chemistry World Blog
Synthetic Nature
Synthesizing Ideas
Carbon-Based Curiosities
Experimental Error
Business|Bytes|Genes|Molecules
Eye on FDA
Sigma-Aldrich ChemBlogs
Chemical Forums
Depth-First
P212121
Curly Arrow
ChemCafe
Power of Goo
Fetz the Chemist
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa
Pharma Blog Review


Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Life of a Lab Rat
Nobel Intent
SciTech Daily
Is This Thing On?
Science Blog
Eastern Blot
FuturePundit
Flags and Lollipops
Aetiology
Gene Expression (I)
Gene Expression (II)
Sciencebase
Pharyngula
Adventures in Ethics and Science
Terra Sigillata
Transterrestrial Musings
Slashdot Science
A Scientist's Life
Living the Scientific Life
Humans in Science
Speculist
Science, Shrimp and Grits
Cosmic Variance
The Capsule
Zeroth Order Approximation
Science Library Blog
Biology News Net


Medical Blogs
Med Tech Sentinel
DB's Medical Rants
Science-Based Medicine
GruntDoc
The Health Care Blog
Respectful Insolence
Black Triangle
Diabetes Mine


Economics and Business
Marginal Revolution
Arnold Kling
The Volokh Conspiracy
Knowledge Problem
The Stalwart


Politics / Current Events
Virginia Postrel
Tinkerty Tonk
Instapundit
Megan McArdle
Mickey Kaus
Colby Cosh
Alien Corn
No Watermelons


Belles Lettres
Two Blowhards
Critical Mass
Arts and Letters Daily
God of the Machine
Armavirumque
About Last Night
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« Recommended Books For Medicinal Chemists, Part One | Main | Climategate and Scientific Conduct »

November 30, 2009

More Binding Site Weirdness

Email This Entry

Posted by Derek

Now here's an oddity: medicinal chemists are used to seeing the two enantiomers (mirror image compounds, for those outside the field) showing different activity. After all, proteins are chiral, and can recognize such things - in fact, it's a bit worrisome when the enantiomers don't show different profiles against a protein target.

There are a few cases known where the two enantiomers both show some kind of activity, but via different binding modes. But I've never seen a case like this, where this happens at the same time in the same binding pocket. The authors were studying inhibitors of a biosynthetic enzyme from Burkholderia, and seeing the usual sorts of things in their crystal structures - that is, only one enantiomer of a racemic mixture showing up in the enzyme. But suddenly of their analogs showed both enantiomers simultaneously, each binding to different parts of the active site.

Interestingly, when they obtained crystal structures of the two pure enantiomers, the R compound looks pretty much exactly as it does in the two-at-once structure, but the S compound flips around to another orientation, one that it couldn't have adopted in the presence of the R enantiomer. The S compound is tighter-binding in general, and calorimetry experiments showed a complicated profile as the concentration of the two compounds was changed. So this does appear to be a real effect, and not just some weirdo artifact of the crystallization conditions.

The authors point out that many other proteins have binding sites that are large enough to permit this sort of craziness (P450 enzymes are a likely candidate, and I'd add PPAR binding sites to the list, too). We still do an awful lot of in vitro testing using racemic mixtures, and this makes a person wonder how many times this behavior has been seen before and not understood. . .

Comments (4) + TrackBacks (0) | Category: Analytical Chemistry | Chemical News | Drug Assays


COMMENTS

1. SP on November 30, 2009 1:34 PM writes...

That sounds like something that could happen fairly often in sites whose natural ligands are some sort of dimer.

Permalink to Comment

2. Chemjobber on November 30, 2009 3:39 PM writes...

For those of us who are less experienced, what is a typical binding site size? How many orders of magnitude larger than the average binding site is a P450 binding site?

Permalink to Comment

3. fragment_boy on November 30, 2009 4:36 PM writes...

TBH I cant see why this is in Angewandte (though it could be classed as one of those weird things they love to publish)

In fragment experiments you can get multiple binding modes - in this case they just have multiple binding modes for different enantiomers which is interesting but not that exciting.

Permalink to Comment

4. philip on December 1, 2009 11:14 AM writes...

A few years ago I saw a crystallography talk about a nanomolar binder that was badly disordered in the binding site. What this said to me is that there is a huge amount of energy to be gained just by taking a greasy molecule out of water and "dissolving" it in a hydrophobic binding pocket. So if you float hydrophobic molecules into an environment where the only places to go are hydrophobic sites, that's what will happen. The fact that enantiomers stick to a protein in different ways is not surprising at all. And it probably has little or no instructive value from a drug design point of view.

Permalink to Comment

POST A COMMENT




Remember Me?



EMAIL THIS ENTRY TO A FRIEND

Email this entry to:

Your email address:

Message (optional):




RELATED ENTRIES
Pfizer's R&D Productivity
Selective Scaffolds
Drug Companies Since 1950
Water and Proteins Inside Cells: Sloshing Around, Or Not?
What The Hey? (Abstract Abstracts, Part II)
Another Blogroll Update
Pfizer's Pearl River Layoffs
Why Don't We Have More Protein-Protein Drug Molecules?